Clinical Trials on PROSTATE CANCER in Belgium

Total 1737 results

Hoffmann-La Roche

Completed

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer

Belgium, Denmark, France, Germany, Portugal, Spain, Turkey, Bosnia and Herzegovina, Italy, Sweden, Finland, Netherlands, Norway, Greece
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

Hepatocellular Carcinoma | Liver Cancer

United States, Canada, Germany, France, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Puerto Rico, Romania, Sing... and more
Pfizer

Completed

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Carcinoma, Non-Small Cell Lung

United States, Netherlands, Canada, Belgium, Spain, United Kingdom, Greece, Germany, Korea, Republic of, Poland, Russian Federation, Denmark, Chile, Colombia, Hungary, Czech Republic, Italy, Thailand, Brazil, Hong Kong, Taiwan, Sl... and more
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Ovarian Cancer

United States, France, Poland, United Kingdom, China, Belgium, Germany, Hong Kong, Taiwan, Spain, Canada, Netherlands, Sweden, Korea, Republic of, Singapore, Russian Federation, Argentina, Brazil, Chile, Australia
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
Telik

Completed

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Ovarian Neoplasms

United States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
Karyopharm Therapeutics Inc
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Endometrial Cancer

United States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia, Germany
Tesaro, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Neoplasms

United States, Canada, Netherlands, Spain, Finland, Belgium, Germany, Israel, Denmark, Sweden, United Kingdom, Poland, Hungary, Norway, Italy, Greece, Czechia, Ukraine, Belarus, Turkey
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
CanariaBio Inc.
Gynecologic Oncology Group; Iqvia Pty Ltd

Active, not recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Peritoneal Carcinoma | Peritoneal Cancer | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma

Korea, Republic of, United States, Taiwan, Czechia, Argentina, Spain, Belgium, Brazil, Chile, Canada, Italy, Hungary, India, Mexico
Novartis Pharmaceuticals
GlaxoSmithKline

Completed

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer

China, United States, Belgium, Austria, Italy, Australia, France, Germany, Japan, Norway, Spain, Sweden, Korea, Republic of, Hong Kong, Denmark, Ireland, Taiwan
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Netherlands, Spain, Japan, China, Germany, United Kingdom, Malaysia, Taiwan, Portugal, France, Italy, Australia, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Singapore, Poland and more
Seagen Inc.
Genmab

Recruiting

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

Cervical Cancer

United States, Canada, Japan, Austria, Belgium, China, France, Korea, Republic of, Netherlands, Singapore, Spain, United Kingdom, Argentina, Brazil, Germany, Norway, Peru, Poland, Finland, Denmark, Ireland, Italy, Czechia, Hungary, Taiwan, Swed... and more
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
Pfizer

Completed

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Carcinoma, Pancreatic Ductal

United States, Netherlands, Canada, Hungary, Spain, United Kingdom, France, Austria, Belgium, Germany, Ireland, Korea, Republic of, Russian Federation, Sweden, South Africa, Italy, Singapore, Taiwan, Australia, India, Argentina, J... and more
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Urinary Bladder Neoplasms

United States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
Novartis Pharmaceuticals

Completed

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

Cancer | Renal Cell Carcinoma (RCC)

United States, Belgium, Canada, Spain, United Kingdom, Turkey, Austria, Argentina, Brazil, Czechia, France, Germany, Israel, Italy, Poland, Russian Federation, Korea, Republic of, Chile, China, Greece, Hungary, Ireland, Slovakia, Japan, Denmar... and more
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
AbbVie

Active, not recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Acute Myeloid Leukemia | Cancer | Multiple Myeloma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States, Australia, Belgium, Canada, Denmark, France, Greece, Hong Kong, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Au...
Corcept Therapeutics
Gynecologic Oncology Group

Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, Korea, Republic of, Poland, Spain, United Kingdom
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Tesaro, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States, Spain, Finland, Czechia, Italy, Denmark, Germany, Belgium, Israel, Canada, Russian Federation, Sweden, United Kingdom, Poland, Ireland, Ukraine, France, Norway, Switzerland, Hungary
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Pfizer

Completed

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Ovarian Cancer

United States, Canada, Australia, France, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Austria, Denmark, Hungary, Singapore, Hong Kong, Belgium, Japan, Ireland, Italy, Netherlands, Czechia, Poland, Switzerland, Russian... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer

United States, Germany, Israel, Canada, China, Australia, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Russian Federation, Turkey and more

Clinical Trials on PROSTATE CANCER in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations